GlassScriptPhysician profile
Julio Vega
NPI 1528564069
$6,409.23
in general payments reported to CMS, 2019-2025
31 companies · $1,998 in 2025
The $1,998 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2021: $298 · 2022: $1,182 · 2023: $155 · 2024: $2,628 · 2025: $1,998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,252 · Travel and Lodging: $1,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,251.76 |
| Travel and Lodging | $1,529.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,396.62 | 2024 | Intellis Adaptivestim |
| Si-Bone, INC. | $1,155.05 | 2025 | |
| Neuropace, INC. | $1,113.81 | 2022 | |
| Boston Scientific Corporation | $317.05 | 2024-2025 | Intracept |
| Axsome Therapeutics, INC. | $281.25 | 2025 | Symbravo |
| Emd Serono, INC. | $260.71 | 2021-2024 | Mavenclad |
| Sk Life Science, INC. | $200.33 | 2024 | Xcopri |
| Stryker Corporation | $192.31 | 2024 | Mild Device Kit |
| Biotronik Nro, INC. | $167.80 | 2025 | Prospera |
| Genentech USA, INC. | $148.90 | 2019 | |
| Genzyme Corporation | $140.65 | 2023 | |
| Tg Therapeutics, INC. | $129.01 | 2025 | |
| Alexion Pharmaceuticals, INC. | $124.99 | 2021 | |
| Ani Pharmaceuticals, INC. | $124.94 | 2024 | Purified Cortrophin Gel |
| E.R. Squibb & Sons, L.L.C. | $120.32 | 2024 | Zeposia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $102.58 | 2025 | Sprint Pns System |
| Neurelis, INC. | $67.70 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $54.18 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $48.39 | 2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $39.37 | 2024 | Aristada, Lybalvi |
| Astrazeneca Pharmaceuticals LP | $38.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.25 | 2024 | Trintellix |
| Amgen INC. | $23.93 | 2021 | |
| Biogen, INC. | $23.48 | 2024 | Vumerity, Tysabri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.45 | 2024 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.68 | 2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $15.25 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $14.17 | 2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $14.15 | 2025 | Ponvory |
| Csl Behring | $13.93 | 2025 | Hizentra |
| Lundbeck LLC | $13.81 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.